Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $67.15 USD
Change Today +0.11 / 0.16%
Volume 4.8M
BAX On Other Exchanges
New York
SIX Swiss Ex
As of 8:04 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/14 - $77.31
52 Week Low
02/20/15 - $65.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $755.0K
Corporate Vice President and President of Bio...
Total Annual Compensation: $833.8K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $651.0K
Corporate Vice President of Human Resources
Total Annual Compensation: $525.3K
Compensation as of Fiscal Year 2014.

baxter international inc (BAX) Key Developments

Baxter International Inc.'s BioScience Business Files for European Approval of Investigational 20% Subcutaneous Immune Globulin Treatment for Primary Immunodeficiency

Baxter International Inc. announced that its BioScience business has submitted a marketing authorization application (MAA) to 17 competent authorities in Europe following the decentralized procedure (DCP) for approval of its investigational 20% concentration subcutaneous immune globulin (IGSC) treatment for primary immunodeficiencies (PI, a group of disorders in which part of the body's immune system is missing or does not function properly). Baxter is advancing the 20% treatment as part of its efforts to expand the primary immunodeficiency treatment portfolio to address patient needs. The filing is based on the positive results of a Phase 2/3 study that evaluated the efficacy, safety, tolerability and pharmacokinetics (PK) of IGSC 20% in European patients at least two years old with PI. The study met its primary endpoint that measured the rate of validated acute serious bacterial infections (VASBIs); these results were initially presented during the 2014 biennial congress of the European Society for Immunodeficiencies (ESID).

Baxter International Inc. to Present New Data at ASCO from Expanding Oncology Pipeline Designed to Address Unmet Needs in Challenging Cancers

Baxter International announced the presentation of new data from its growing oncology portfolio at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 29 - June 2, 2015 in Chicago, Ill. Full Phase III results of the investigational treatment pacritinib for myelofibrosis will be featured in an ASCO press briefing and in a late-breaking oral presentation. This presentation follows the announcement of the topline results from the study in March 2015. Data presented at ASCO will provide more details on the findings of the PERSIST-1 study, including primary and secondary endpoints. Pacritinib is a multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated for the treatment of myelofibrosis, a chronic malignant bone marrow disorder that promotes abnormal blood cell production. Patients with this condition have limited treatment options, particularly those with low platelet counts as a result of their disease or a side effect from their current treatment, and urgently need novel therapies to increase survival and improve quality of life. Pacritinib is being jointly developed by CTI BioPharma Corp. and Baxter BioScience. Additional data from Baxter BioScience at ASCO includes a summary of the early stage research on imalumab (BAX069) being evaluated for the treatment of metastatic colorectal cancer. Two posters will feature early-stage results - one including a first-in-human, Phase I study in advanced solid tumors and a second trial-in-progress poster of a Phase Ib/IIa proof-of-concept study.

Baxter International Inc. Presents at FT Asia Pharma Healthcare Summit, May-20-2015 02:15 PM

Baxter International Inc. Presents at FT Asia Pharma Healthcare Summit, May-20-2015 02:15 PM. Venue: InterContinental, 80 Middle Road, Singapore, Singapore. Speakers: Shankar Kaul, President and Region Head, Emerging Asia.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $67.15 USD +0.11

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,818 JPY -2.50
Kimberly-Clark Corp $109.73 USD -0.60
Mylan NV $72.68 USD +0.64
Stryker Corp $96.24 USD -0.35
Takeda Pharmaceutical Co Ltd ¥6,066 JPY +18.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BAX Industry Range
Price/Earnings 19.7x
Price/Sales 2.2x
Price/Book 5.0x
Price/Cash Flow 15.4x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at